Cytokinetics Inc (CYTK) 13F Positioning & Ownership Changes (Q2 2026)

CYTK ranks #1205 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CYTK is a top-conviction position for Royalty Pharma Sub-Manager, LLC — at 34.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CYTK belongs to BlackRock, Inc., but the position matters far more to Royalty Pharma Sub-Manager, LLC, who has 34.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its CYTK position for two straight quarters, increasing it by $670.1M to reach $1.7B today.

Fidelity has trimmed its CYTK position for two straight quarters, cutting it by $385.1M while still holding $428.7M.

CYTK is up 0.7% today, and institutions have been net buyers of $2.4B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CYTK reported a net loss of $894.0M over the trailing twelve months.

• Not yet profitable — net loss of $894.0M over the trailing twelve months
• Revenue declined 21.1% year over year
• Net income declined year over year, from -$606.3M to -$894.0M
• Operating cash flow was negative, using $510.0M in cash
• Current ratio of 4.53x — enough short-term assets to cover short-term liabilities